【摘要】：近年來隨著上市企業(yè)數(shù)量不斷增加,醫(yī)藥行業(yè)作為國民經(jīng)濟的一個重要組成部分,其上市企業(yè)數(shù)量也在迅猛增加。雖然醫(yī)藥行業(yè)的景氣度較高,但并非所有醫(yī)藥上市企業(yè)都能順應(yīng)景氣度高的態(tài)勢而快速成長,該行業(yè)的上市企業(yè)也同樣是良莠不齊,如何判斷上市企業(yè)的成長性是許多投資者所關(guān)心的焦點問題。財務(wù)報表分析作為分析企業(yè)財務(wù)狀況主要工具在構(gòu)建企業(yè)成長性財務(wù)指標(biāo)起到很重要的作用,因此在基于財務(wù)報表視角下找出影響企業(yè)成長性的影響因素主要以內(nèi)在因素占多數(shù),但成長性的影響因素是多方面的,不僅包括財務(wù)因素的影響,還包括非財務(wù)因素的影響。 文章主要通過運用企業(yè)成長價值、企業(yè)成長性評價以及企業(yè)生命周期等相關(guān)理論和研究方法并結(jié)合企業(yè)財務(wù)報表相關(guān)理論,構(gòu)建了影響醫(yī)藥上市企業(yè)成長性的指標(biāo)評價體系。以財務(wù)報表反映的數(shù)據(jù)為依據(jù),通過運用不同的報表數(shù)據(jù)分析方法找出影響企業(yè)成長性的財務(wù)指標(biāo)。根據(jù)生物醫(yī)藥公司的特點,從財務(wù)與非財務(wù)方面構(gòu)建成長性指標(biāo)評價體系。財務(wù)指標(biāo)主要包括4個一級指標(biāo)和10個二級指標(biāo),非財務(wù)指標(biāo)包括3個,分別為公司規(guī)模、市場環(huán)境、以及自主創(chuàng)新能力,并通過因子分析評價方法和SPASS統(tǒng)計軟件進(jìn)行驗證,綜合分析影響企業(yè)成長性的內(nèi)外因素。其中,除財務(wù)因素外,公司規(guī)模、市場需求、國家政策、自主創(chuàng)新能力都在不同程度上影響公司的成長。文章主要通過對成長性指標(biāo)體系的構(gòu)建以及運用因子分析法對指標(biāo)進(jìn)行評價并結(jié)合天壇生物股份有限公司為案例,通過對該企業(yè)指標(biāo)系數(shù)與行業(yè)指標(biāo)系數(shù)的對比,找出影響該企業(yè)成長的問題并提出解決問題的對策及建議。這不僅有利于企業(yè)產(chǎn)業(yè)結(jié)構(gòu)調(diào)整、盈利能力的提高：還有利于企業(yè)不斷改善經(jīng)營管理,提高市場競爭能力并在生物醫(yī)藥行業(yè)中不斷的發(fā)展,從而獲得成長。
[Abstract]:In recent years, with the increasing number of listed enterprises, the pharmaceutical industry as an important part of the national economy, the number of listed enterprises is also increasing rapidly. Although the pharmaceutical industry has a relatively high degree of vitality, not all listed pharmaceutical companies can adapt to the situation of high Jing tolerance and grow rapidly. The listed enterprises in this industry are also mixed. How to judge the growth of listed enterprises is the focus of many investors. As the main tool to analyze the financial situation of enterprises, financial statement analysis plays an important role in the construction of enterprise growth financial indicators. Therefore, based on the perspective of financial statements, we find out that the main factors affecting the growth of enterprises are internal factors, but the influence factors of growth are various, including not only the financial factors, but also the non-financial factors. By using the relevant theories and research methods of enterprise growth value, enterprise growth evaluation and enterprise life cycle, and combining with the relevant theory of enterprise financial statements, this paper constructs an index evaluation system that affects the growth of pharmaceutical listed enterprises. Based on the data reflected in the financial statements, this paper finds out the financial indicators that affect the growth of enterprises by using different data analysis methods. According to the characteristics of biopharmaceutical companies, a growth index evaluation system is constructed from financial and non-financial aspects. Financial indicators mainly include 4 first-class indicators and 10 second-class indicators, while non-financial indicators include three, which are company size, market environment, and independent innovation ability, respectively, and are verified by factor analysis and evaluation method and SPASS statistical software. Comprehensive analysis of internal and external factors affecting the growth of enterprises. Besides financial factors, company size, market demand, national policy and independent innovation ability all affect the growth of the company to some extent. This paper mainly through the construction of the growth index system and the use of factor analysis to evaluate the indicators and combined with Temple of Heaven Biological Co., Ltd. as a case, through the comparison between the index coefficient of the enterprise and the industry index coefficient. Find out the problems that affect the growth of the enterprise and put forward the countermeasures and suggestions to solve the problems. This is not only conducive to the adjustment of the industrial structure and the improvement of profitability, but also to the continuous improvement of management, the improvement of market competitiveness and the continuous development in the biomedical industry.
【學(xué)位授予單位】：哈爾濱商業(yè)大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：F406.7;F426.72

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 一葦;;運轉(zhuǎn)生命之舟——訪天壇生物公司董事長倪道明[J];中關(guān)村;2003年08期

2 ;天壇生物打造國內(nèi)最大疫苗產(chǎn)業(yè)化基地[J];醫(yī)藥工程設(shè)計;2009年06期

3 楊彬;天壇生物的風(fēng)險因素和對策[J];中國科技信息;1999年13期

4 劉霏;;假冒人血白蛋白使天壇生物“蒙冤”[J];首都醫(yī)藥;2007年11期

5 ;天壇生物:或受益疫苗安全問題[J];股市動態(tài)分析;2014年01期

6 賀平鴿;;G天壇 高成長自今開始[J];證券導(dǎo)刊;2006年29期

7 ;天壇生物開建國內(nèi)最大生物疫苗基地[J];化工中間體;2010年06期

8 徐欣馳;;醫(yī)藥公司財務(wù)分析與公司估值——以天壇生物為例[J];中國經(jīng)貿(mào)導(dǎo)刊;2013年26期

9 梁冬冬;;天壇生物 疫苗行業(yè)處于高增長期[J];證券導(dǎo)刊;2008年34期

10 婁圣睿;;天壇生物:獲得甲型H1N1流感疫苗毒株[J];股市動態(tài)分析;2009年25期

相關(guān)重要報紙文章 前10條

1 白玉;天壇生物與長生所“再續(xù)前緣”[N];中國醫(yī)藥報;2006年

2 天相投資 楊淳邋施劍剛;天壇生物 去年業(yè)績符合預(yù)期[N];中國證券報;2008年

3 東吳證券研究所 王光清;天壇生物 放手打造疫苗產(chǎn)業(yè)[N];中國證券報;2004年

4 華泰證券投資策略部 任飛;天壇生物：年報業(yè)績乏善可陳[N];醫(yī)藥經(jīng)濟報;2002年

5 彭海柱;天壇生物 外延性增長空間巨大[N];中國證券報;2006年

6 林U，

本文編號：2165071